Assessment and Initiation of Sildenafil Therapy for Erectile Dysfunction

Cardiovascular Safety

Contraindication with nitrates – Concurrent use of nitrate medications (including recreational “poppers”) can precipitate life‑threatening hypotension; therefore sildenafil must not be prescribed in patients taking nitrates. 1

Comorbid conditions influencing therapy – Diabetes, renal or hepatic impairment, bleeding disorders, peptic ulcer disease, and retinitis pigmentosa should be identified before initiating sildenafil, as they affect dosing and safety considerations. [2][1]
Baseline metabolic labs – A fasting glucose and lipid profile should be obtained to assess cardiovascular risk and guide overall management. 2
Testosterone assessment – A morning total testosterone measurement is required; if the result is <300 ng/dL, bioavailable or free testosterone should be measured to evaluate hypogonadism. [2][1]
Psychosocial screening – Screening for depression, anxiety, and relationship conflict is recommended, with referral to psychotherapy for predominantly psychogenic erectile dysfunction. 1

Standard initiation – Begin sildenafil at 50 mg taken about one hour before sexual activity, with a maximum of one dose per day. 1
Reduced starting dose – Use a 25 mg starting dose in patients with severe renal or hepatic disease. 1
Titration – If the 50 mg dose is ineffective and well tolerated, increase to 100 mg; most men ultimately require 50–100 mg for optimal efficacy. [1][2]

Need for sexual stimulation – Emphasize that sildenafil requires sexual arousal to work; it does not cause spontaneous erections.
Timing and food effects – Instruct patients to take the medication approximately one hour before intercourse; high‑fat meals may delay onset.
Trial period – Multiple attempts may be necessary to determine the most effective dose and timing. 1

Common side effects – Headache, facial flushing, dyspepsia, nasal congestion, back pain, myalgia, visual disturbances, and dizziness are the most frequently reported events; they are generally mild‑to‑moderate and dose‑dependent. [2][1]

Hypogonadism – In men with testosterone < 300 ng/dL and related symptoms, adding testosterone therapy to sildenafil improves erectile outcomes compared with sildenafil alone. [2][1]
Non‑responders – For patients who do not achieve satisfactory erections:
- Verify correct medication use and timing. 2
- Confirm adequate sexual stimulation. 1
- Consider dose escalation to 100 mg. 1
- Re‑evaluate for hypogonadism and initiate testosterone therapy if indicated. 2

Impact of comorbidities – Men with diabetes or a history of prostate surgery exhibit lower response rates to sildenafil compared with the general population. 1

For short‑acting agents (e.g., sildenafil, vardenafil, avanafil), nitrates should not be administered until at least 24 hours have elapsed since the last PDE5 inhibitor dose.
For the long‑acting agent (tadalafil), nitrates should be withheld for at least 48 hours after the last dose.
These timing restrictions are intended to prevent synergistic hypotension when nitrates are combined with PDE5 inhibitors. 3

Concomitant use of alpha‑blockers (prescribed for hypertension or benign prostatic hyperplasia) increases the risk of orthostatic hypotension when combined with any PDE5 inhibitor.
Clinicians should employ precautionary measures, such as initiating both drugs at the lowest effective doses and monitoring blood pressure closely.
The risk is less pronounced in patients who have been on a stable alpha‑blocker regimen for an extended period. 3

Severe renal disease: PDE5 inhibitors are generally not recommended because of markedly reduced drug clearance.
Severe hepatic disease: PDE5 inhibitors are generally not recommended due to impaired metabolism.
Mild to moderate renal or hepatic impairment: Initiate therapy with lower doses of PDE5 inhibitors to account for delayed drug metabolism and avoid accumulation.
These recommendations aim to balance efficacy with safety in patients with compromised organ function. 3

In individuals with spinal cord injury, PDE5 inhibitors should be prescribed with caution, and a lower initial dose is advised to mitigate potential hemodynamic effects. 3

For patients receiving anticoagulant therapy or those with inherent bleeding disorders, the evidence does not designate PDE5 inhibitors as a formal contraindication.
Nevertheless, clinicians should exercise caution and consider alternative treatments (e.g., vacuum erection devices) when appropriate, acknowledging the limited data on bleeding risk. 4